ERBB2 and breast cancer: At the same time, the differentially methylated sites could not only clearly distinguish pCR and non-pCR samples, but also distinguish non-pCR patients before and after treatment (Figures 1C, D), emphasizing the potential impact of methylation changes on the treatment response of HER2-positive breast cancer.